XIV Eurasian Hematology-Oncology Congress - EHOC 2023

 

XIV Eurasian Hematology-Oncology Congress - EHOC 2023
M

Case Discussion: Ven+Aza Maintanance After Intensive Induction in 33 y/o Intermediate-Risk AML Patient

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Mehmet Yilmaz
By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Mehmet Yilmaz
2 views
February 15, 2024
0 Comments
Login to view comments. Click here to Login
Leukemia
17:15
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Clinical Case of BPDCN

Feat. H. Hamed
19:51
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A 50-Year Personal Perspective on the Treatment of AML

Feat. C. Schiffer
12:11
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Induction Therapy Choices and Responses of ALL in a Third World Coun…

Feat. A. Zafar
14:43
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Is HSCT Necessary to Consolidate Hematological Remission After CAR-T…

Feat. F. Saglio
07:25
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

BK Virus Infections in Pediatric Leukemia During Treatment

Feat. D. KaçAr
08:11
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Molecular Characteristics and Treatment Response to COG-ALL Protocol…

Feat. B. GüNer Yılmaz
13:09
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Inaticabtagene Autoleucel Treatment in Adult R/R B-Cell ALL in China

Feat. L. Lulu
16:52
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CLL: Future Perspectives and Unanswered Questions

Feat. A. Ferrajoli
15:36
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in CLL: The Case for Combination Therapy in 1L

Feat. A. Ibrahim
12:23
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in CLL: The Case for BTKi Monotherapy in 1L

Feat. G. Musuraca
06:14
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CLL Case Presentation: 72 y/o Male With Cardiac Comorbidities

Feat. F. Eda Nuhoğlu Kantarcı
08:11
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

State-of-the-Art in CLL Treatment

Feat. A. Cuneo
08:54
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Future Perspectives in CML

Feat. N. Chaudhri
07:46
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in CML: Imatinib is NOT the Best Choice for 1L TKI

Feat. T. Sacha
13:06
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in CML: Imatinib is the Best Choice for 1L TKI

Feat. G. Saglio
14:31
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CML Case Presentation: A Patient With Multiple TKI Failure

Feat. D. Özmen İbiş
12:22
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CML Case Presentation: A Young Patient With TKI Intolerance and Resi…

Feat. C. Fava
14:44
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CML: State-of-the-Art and Progress Towards Cure

Feat. P. Raanani
20:06
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Current and Future Approaches to the Treatment of B- and T-ALL

Feat. D. Hoelzer
18:14
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Acute Promyelocytic Leukemia: Risk Stratification and New Treatment …

Feat. S. ÇAkı Kılıç
16:07
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Pediatric AML: Diagnosis and Risk Stratification

Feat. N. Karadaş
26:45
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Therapeutic Challenges and BMT in Pediatric Patients With CML

Feat. T. Ileri
26:32
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Pediatric CML Treatment Options and Management

Feat. O. TüFekçI GüRocak
08:29
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Effect of GVHD Prophylaxis on the Leukemia-Free Survival in Pediatri…

Feat. O. Aylin Boran
15:56
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Pediatric CML Diagnosis

Feat. A. Meral Güneş
08:34
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Adults With ALL: When Not to Transplant

Feat. E. Jabbour
13:19
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Adults With ALL: When to Transplant

Feat. S. Chiaretti
08:39
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Feasibilty of Therapy for Elderly Ph+ ALL Patients

Feat. G. Marconi
15:43
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Recent Updates in ALL Treatment

Feat. G. Martinelli
14:12
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Future Directions in AML: Optimizing Doublets and Triplets to Improv…

Feat. N. Daver
05:14
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Case Discussion: Ven+Aza Maintanance After Intensive Induction in 33…

Feat. M. Yilmaz
11:17
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

State of the Art: Role of Maintenance Therapy in AML

Feat. Z. Aziz